• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

BioCryst re­sumes en­roll­ment for im­mune dis­eases drug; Ea­gle buys stake in res­pi­ra­to­ry dis­ease biotech

3 years ago
News Briefing

Verona’s COPD drug shines in PhI­II study, po­ten­tial­ly clear­ing path to FDA — shares jump

3 years ago
R&D

BeiGene touts pos­i­tive PhI­II da­ta on tislelizum­ab in af­ter­math of set­backs at FDA

3 years ago
R&D

Up­dat­ed: FDA slaps Ama­zon with a warn­ing let­ter for sell­ing OTC mole re­moval prod­ucts

3 years ago
FDA+

On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

3 years ago
Deals
Outsourcing

Covid-19 roundup: De­sert­ed by Roche and plagued by set­backs, Atea march­es on; Eu­rope lines up or­der for Mod­er­na's ...

3 years ago
Coronavirus

Rea­ta’s ‘reg­u­la­to­ry con­cerns’ turn in­to three-month de­lay on FDA de­ci­sion for Friedre­ich’s atax­ia drug

3 years ago
R&D
FDA+

Mer­ck makes first big splash for Alzheimer’s drug R&D since 2017 fail, ink­ing re­search pact with Cere­vance

3 years ago
Deals

Ko­di­ak man­ages to score a win for its Eylea ri­val — but the ma­jor test is still ahead

3 years ago
R&D

Karuna looks to build on pos­i­tive schiz­o­phre­nia da­ta with one of the biggest pub­lic rais­es this year

3 years ago
Financing

CorMedix hit with sec­ond CRL for an­ti­fun­gal treat­ment, cit­ing man­u­fac­tur­ing and API is­sues

3 years ago
FDA+
Manufacturing

Why non-opi­oid pain drugs keep fail­ing — and what's next for the field

3 years ago
R&D
In Focus

US to stop sup­ply­ing Lil­ly's mAb for Covid-19 this month as com­mer­cial mar­ket awaits

3 years ago
Pharma
Coronavirus

Math­ai Mam­men makes an abrupt ex­it as head of the big R&D group at J&J

3 years ago
People

No­vavax shares shred­ded as Covid vac­cine sales fall more than 90% in Q2

3 years ago
Pharma

In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

3 years ago
Deals
Pharma

De­spite falling Covid-19 sales, BioN­Tech main­tains '22 sales guid­ance

3 years ago
Pharma

With drug pric­ing al­most done, Con­gress looks to wrap up FDA user fee leg­is­la­tion

3 years ago
FDA+
Law

GSK and IQVIA launch plat­form of US vac­ci­na­tion da­ta, show­ing drop in adult rates

3 years ago
Pharma

Ab­b­Vie sur­veys emo­tion­al im­pact of chron­ic leukemia con­di­tion, finds 'roller coast­er' of emo­tions

3 years ago
Pharma
Marketing

As­traZeneca and Dai­ichi Sankyo sprint to mar­ket af­ter FDA clears En­her­tu in just two weeks

3 years ago
Pharma
FDA+

FDA's vac­cine ad­comm to re­view first fe­cal trans­plant to treat C. dif­fi­cile in­fec­tions

3 years ago
Pharma
FDA+

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

3 years ago
People
Cell/Gene Tx

UniQure halts high-dose treat­ments of Hunt­ing­ton's drug af­ter 3 pa­tients hos­pi­tal­ized — shares tank

3 years ago
R&D
Cell/Gene Tx
First page Previous page 482483484485486487488 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times